PRM Stock Overview
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Proteome Sciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.035 |
| 52 Week High | UK£0.088 |
| 52 Week Low | UK£0.027 |
| Beta | -0.022 |
| 1 Month Change | 6.36% |
| 3 Month Change | -23.53% |
| 1 Year Change | -14.18% |
| 3 Year Change | -46.00% |
| 5 Year Change | 28.10% |
| Change since IPO | -97.81% |
Recent News & Updates
Recent updates
Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth Watching
Dec 02
Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors
Aug 25Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors
Dec 22Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?
Sep 03Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)
Jan 27Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?
May 31Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E
Apr 04Shareholder Returns
| PRM | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 6.4% | -1.1% | 2.2% |
| 1Y | -14.2% | -46.8% | 0.9% |
Return vs Industry: PRM exceeded the UK Life Sciences industry which returned -46.8% over the past year.
Return vs Market: PRM underperformed the UK Market which returned 0.9% over the past year.
Price Volatility
| PRM volatility | |
|---|---|
| PRM Average Weekly Movement | 11.6% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: PRM's share price has been volatile over the past 3 months.
Volatility Over Time: PRM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 35 | Mariola Sohngen | www.proteomics.com |
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers, as well as bioinformatics tools.
Proteome Sciences plc Fundamentals Summary
| PRM fundamental statistics | |
|---|---|
| Market cap | UK£10.36m |
| Earnings (TTM) | -UK£2.44m |
| Revenue (TTM) | UK£5.03m |
2.1x
P/S Ratio-4.2x
P/E RatioIs PRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRM income statement (TTM) | |
|---|---|
| Revenue | UK£5.03m |
| Cost of Revenue | UK£3.38m |
| Gross Profit | UK£1.65m |
| Other Expenses | UK£4.09m |
| Earnings | -UK£2.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 32.76% |
| Net Profit Margin | -48.59% |
| Debt/Equity Ratio | -366.4% |
How did PRM perform over the long term?
See historical performance and comparison